Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest Expenses (2021 - 2025)

Fennec Pharmaceuticals' Interest Expenses history spans 10 years, with the latest figure at $308000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 68.12% year-over-year to $308000.0, compared with a TTM value of $2.1 million through Dec 2025, down 48.88%, and an annual FY2025 reading of $2.1 million, down 48.88% over the prior year.
  • Interest Expenses for Q4 2025 was $308000.0 at Fennec Pharmaceuticals, down from $586000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $1.0 million in Q2 2024, with the low at $4000.0 in Q1 2021.
  • Average Interest Expenses over 5 years is $566263.2, with a median of $594000.0 recorded in 2025.
  • Year-over-year, Interest Expenses soared 1350.0% in 2022 and then tumbled 68.12% in 2025.
  • Tracing FENC's Interest Expenses over 5 years: stood at $55000.0 in 2021, then soared by 1561.82% to $914000.0 in 2022, then grew by 0.11% to $915000.0 in 2023, then rose by 5.57% to $966000.0 in 2024, then tumbled by 68.12% to $308000.0 in 2025.
  • Per Business Quant, the three most recent readings for FENC's Interest Expenses are $308000.0 (Q4 2025), $586000.0 (Q3 2025), and $594000.0 (Q2 2025).